Jason Luke: Excited to speak at the SITC Spring Scientific – Cellular Therapy for Solid Tumors
Jason Luke, Associate Director for Clinical Research at Hillman Cancer Center and Director of the Immunotherapy and Drug Development Center, shared a post on X:
“Excited to speak at the Society for Immunotherapy of Cancer (SITC) Spring Scientific: Cellular Therapy for Solid Tumors – March 12–14, San Diego.
I’ll discuss Development, Clinical Efficacy and Translational Analysis of PRAME Targeting with TCR Transduced T cells via IMA203. Hope you’ll join us!”
More posts featuring Jason Luke.
Jason J. Luke, MD, FACP, FASCO, is the Associate Director for Clinical Research at Hillman Cancer Center and Director of the Immunotherapy and Drug Development Center. He also serves as an Associate Professor of Medicine in the Division of Hematology/Oncology at the University of Pittsburgh School of Medicine.
Dr. Luke specializes in early-phase drug development, particularly novel immunotherapeutics and biomarkers, with a focus on solid tumors and malignant melanoma. His clinical interests include Phase I trials, cancer immunotherapy, and drug development.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023